Vote Scores

Home / Companies / BioXcel Therapeutics, Inc. / 10 Jun 2024

Meeting · year to 30 June 2024133 filers reporting

BioXcel Therapeutics, Inc.: meeting of 10 Jun 2024

Votes reported on Form N-PX, item by item

133 Form N-PX filers reported votes at the BioXcel Therapeutics, Inc. meeting of 10 Jun 2024. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

2 nominees; 60.1% of reported votes for; 38 filers withheld from or voted against at least one nominee.

160 vote records from 47 filers. 2 of the 47 filers that marked the item either way voted against management.

19.1% for0.0% against80.9% other4.3% against management47 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

179 vote records from 131 filers. 74 of the 127 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.

40.5% for56.5% against3.1% other58.3% against management131 filers58.7% for41.3% against41.3% against management8,463,711 reported shares
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 126 filers; three years: 1 filer; for: 1 filer; against: 1 filer; : 1 filer; not applicable: 1 filer.

182 vote records from 133 filers. 1 of the 129 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.

0.8% for0.0% against99.2% other0.8% against management133 filers0.0% for0.3% against99.7% other0.3% against management8,509,099 reported shares
4

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

80 vote records from 47 filers. 0 of the 47 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management47 filers100.0% for0.0% against0.0% against management1,909,777 reported shares
5

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

80 vote records from 47 filers. 7 of the 47 filers that marked the item either way voted against management.

85.1% for14.9% against14.9% against management47 filers70.2% for29.8% against29.8% against management1,909,777 reported shares, counted once per item in this group
6

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

160 vote records from 47 filers. 2 of the 47 filers that marked the item either way voted against management.

76.6% for4.3% against19.1% other4.3% against management47 filers84.6% for15.4% against15.4% against management3,819,554 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Pay-vote frequency4. Auditor
VanguardForForSplit or no voteFor
BlackRock and iSharesSplit or no voteAgainst *Split or no voteFor
FidelityAbstain or withhold *Against *Split or no voteFor
DimensionalNo reportAgainst *Split or no vote *No report
State Street and SPDRSplit or no voteForSplit or no voteFor
InvescoSplit or no voteForSplit or no voteFor
EquitableSplit or no voteAgainst *Split or no voteFor
Charles SchwabSplit or no voteForSplit or no voteFor
Nuveen and TIAANo reportAgainst *Split or no voteNo report
ProShares and ProFundsSplit or no voteAgainst *Split or no voteFor
John Hancock and ManulifeSplit or no voteAgainst *Split or no voteFor
Morgan Stanley, Eaton Vance and CalvertSplit or no voteAgainst *Split or no voteFor
J.P. MorganNo reportAgainst *Split or no voteNo report
Goldman SachsNo reportAgainst *Split or no voteNo report
PGIM and PrudentialNo reportForSplit or no voteNo report
Northern Trust and FlexSharesSplit or no voteForSplit or no voteFor
SEISplit or no voteForSplit or no voteFor
T. Rowe PriceForAgainst *Split or no voteFor
Lincoln FinancialSplit or no voteForSplit or no voteFor
VoyaSplit or no voteAgainst *Split or no voteFor
NationwideSplit or no voteAgainst *Split or no voteFor
Victory CapitalSplit or no voteAgainst *Split or no voteFor
Guggenheim and RydexSplit or no voteAgainst *Split or no voteFor
Columbia ThreadneedleSplit or no voteAgainst *Split or no voteFor
BNY MellonNo reportForSplit or no voteNo report
PrincipalSplit or no voteAgainst *Split or no voteFor
Pacific Life fundsSplit or no voteAgainst *Split or no voteFor
Global XSplit or no voteForSplit or no voteFor
Federated HermesForForSplit or no voteFor
AllianceBernsteinNo reportAgainst *Split or no voteNo report
DWSSplit or no voteAgainst *Split or no voteFor
MassMutualNo reportForSplit or no voteNo report
Janus HendersonNo reportAgainst *Split or no voteNo report
Neuberger BermanNo reportForSplit or no voteNo report
BairdNo reportAgainst *Split or no voteNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the BioXcel Therapeutics, Inc. meeting?

133 Form N-PX filers reported votes at the meeting of 10 Jun 2024. On say-on-pay, 74 of 127 voted against management (58.3%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by BioXcel Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for BioXcel Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing BioXcel Therapeutics, Inc. with a meeting date within three days of 10 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.